Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic diseases including obesity, metabolic disorders, and pulmonary conditions by targeting G-protein coupled receptors (GPCRs), which are involved in approximately one in three marketed medicines. The company uses a proprietary structure-based drug discovery platform combined with computational chemistry to design selective oral modulators as alternatives to injectable biologics and peptide therapies, offering improved patient accessibility, manufacturing scalability, and dose administration. Its lead program is aleniglipron, a GLP-1 receptor agonist in clinical development for obesity, while other programs target amylin, GIPR, glucagon, and LPA1 receptors; the company generates revenue through upfront payments and royalties from strategic partnerships and licensing agreements with pharmaceutical partners.